Experimental Approaches to Cognitive Disturbance in Alzheimer's Disease

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Harvard Review of Psychiatry

• Publication date

  1998-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3109/10673229809010950PMID 10370429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous nicotine in Alzheimer's disease: a pilot study

  2004cited by this paper
• Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent

  2004cited by this paper
• Memory enhancement: Supra-additive effect of subcutaneous cholinergic drug combinations in mice

  2004cited by this paper
• Risk of Alzheimer's disease and duration of NSAID use

  1998cited by this paper
• Psychopharmacology: The Fourth Generation of Progress

  1998cited by this paper
• No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.

  1997cited by this paper
• Apolipoprotein E genotype and cognition in the very old.

  1997cited by this paper
• SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats.

  1997cited by this paper
• A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• Donepezil (Aricept) for Alzheimer's disease.

  1997cited by this paper
• Risk of Alzheimer's disease and duration of NSAID use

  1997cited by this paper
• A Risk-Benefit Assessment of Tacrine in the Treatment of Alzheimer’s Disease

  1997cited by this paper
• Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice

  1997cited by this paper
• The Pathogenesis of Senile Plaques

  1997cited by this paper
• Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans.

  1997cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Double-Blind, Placebo-Controlled Study of Metrifonate, an Acetylcholinesterase Inhibitor, for Alzheimer Disease

  1996cited by this paper
• Searching for drugs that combat Alzheimer's.

  1996cited by this paper
• Neurodegenerative Disease: Searching for Drugs That Combat Alzheimer's

  1996cited by this paper
• Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils

  1996cited by this paper
• 578 Galanthamine hydrobromide — Interim results of a group comparative, placebo controlled, study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer's type

  1996cited by this paper
• 645 Nerve Growth Factors as a Treatment of Alzheimer's Disease

  1996cited by this paper
• A pilot study of prednisone in Alzheimer's disease.

  1996cited by this paper
• Theα2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type

  1996cited by this paper
• IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells.

  1996cited by this paper
• Medicare HMOs develop plan for future of Alzheimer's programming.

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial

  1996cited by this paper
• α2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat

  1996cited by this paper
• Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules

  1996cited by this paper
• Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

  1996cited by this paper
• Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease

  1996cited by this paper
• Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology

  1996cited by this paper
• Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils.

  1996cited by this paper
• K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs.

  1996cited by this paper
• Efficacy and safety of idebenone in the long‐term treatment of Alzheimer's Disease: a double‐blind, placebo controlled multicentre study

  1996cited by this paper
• Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease

  1996cited by this paper
• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

  1996cited by this paper
• Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

  1996cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Antagonism of scopolamine-induced memory impairments in rats by the muscarinic agonist RU 35,926 (CI-979).

  1995cited by this paper
• Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications.

  1995cited by this paper
• Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.

  1995cited by this paper
• Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits

  1995cited by this paper
• Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease

  1995cited by this paper
• Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

  1995cited by this paper
• Candidate gene for the chromosome 1 familial Alzheimer's disease locus

  1995cited by this paper
• Nicotinic and muscarinic receptors in the rat prefrontal cortex: Differential roles in working memory, response selection and effortful processing

  1995cited by this paper
• The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's Disease

  1995cited by this paper
• Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

  1995cited by this paper
• Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.

  1995cited by this paper
• Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity

  1995cited by this paper
• Beta APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer's disease-1 family.

  1995cited by this paper
• The Role of β-Amyloid in the Development of Alzheimer’s Disease

  1995cited by this paper
• Antischistosomal drugs: past, present ... and future?

  1995cited by this paper
• Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease.

  1995cited by this paper
• Contrasting effects of clonidine and diazepam on tests of working memory and planning

  1995cited by this paper
• Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.

  1995cited by this paper
• Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.

  1995cited by this paper
• Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy

  1995cited by this paper
• Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type.

  1994cited by this paper
• Estrogen deficiency and risk of Alzheimer's disease in women.

  1994cited by this paper
• Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type.

  1994cited by this paper
• Aniracetam

  1994cited by this paper
• Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.

  1994cited by this paper
• Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

  1994cited by this paper
• AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease.

  1994cited by this paper
• Tacrine alters the secretion of the beta‐amyloid precursor protein in cell lines

  1994cited by this paper
• Inflammatory mechanisms in Alzheimer's disease: implications for therapy.

  1994cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• Human nicotinic receptors--their role in aging and dementia.

  1994cited by this paper
• Enhanced aggregation and β structure of amyloid β peptide after coincubation with C1Q

  1994cited by this paper
• Pharmacokinetics and pharmacodynamics of metrifonate in humans.

  1994cited by this paper
• The impact of microglia-derived cytokines upon gliosis in the CNS.

  1994cited by this paper
• Alzheimer's disease: pathophysiology and the hope for therapy.

  1994cited by this paper
• A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

  1994cited by this paper
• Minimizing bias in industry-sponsored outcomes research.

  1994cited by this paper
• Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q.

  1994cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

  1993cited by this paper
• Clinical trial of indomethacin in Alzheimer's disease

  1993cited by this paper
• Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group.

  1993cited by this paper
• beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease.

  1993cited by this paper
• Using the subcortically lesioned rat cortex to understand the physiological role of amyloid precursor protein.

  1993cited by this paper
• β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease

  1993cited by this paper
• Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

  1993cited by this paper
• K‐252b Selectively Potentiates Cellular Actions and trk Tyrosine Phosphorylation Mediated by Neurotrophin‐3

  1992cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Idebenone in senile dementia of Alzheimer type: a multicentre study.

  1992cited by this paper
• Neuroreceptor changes in Alzheimer disease.

  1992cited by this paper
• Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor.

  1992cited by this paper
• Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report)

  1992cited by this paper
• Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report).

  1992cited by this paper
• Cholinomimetic therapy in Alzheimer's disease.

  1992cited by this paper
• Aniracetam (Ro 13-5057) for the Treatment of Senile Dementia of Alzheimer Type: Results of a Multicentre Clinical Study

  1991cited by this paper
• Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study.

  1991cited by this paper
• Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates

  1991cited by this paper
• Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures.

  1991cited by this paper
• A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease.

  1991cited by this paper

• Smoking Habits in Financial Markets: Nicotine, Stock Returns and Rationality

  2026cites this paper
• Natural Antioxidants: An Effective Strategy for the Treatment of Alzheimer's Disease at the Early Stage.

  2024cites this paper
• Demyelination in the medial prefrontal cortex by withdrawal from chronic nicotine causes impaired cognitive memory.

  2023cites this paper
• The Acute Effects of Nicotine and Exercise on Working Memory

  2016cites this paper
• Современные подходы к терапии при болезни Альцгеймера: от амилоида к поиску новых мишеней

  2014cites this paper
• Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer's disease.

  2012cites this paper
• Influence of nicotinic system and nitric oxide on morphine-induced amnesia

  2011cites this paper
• ATTENTIONAL EFFECTS OF NICOTINE Event-Related Potentials as an Index of the Attentional Effects of Nicotine

  2010cites this paper
• Lack of Association Between Down Syndrome and Polymorphisms in Dopamine Receptor D4 and Serotonin Transporter Genes

  2008cites this paper
• The benefits and drawbacks of nicotine exposure in the cortex and hippocampus of old rats.

  2007cites this paper
• Influence of acute and sub-chronic nicotine pretreatment on morphine state-dependent learning.

  2006cites this paper
• The Effect and Chronic Acute Pre-Treatment with Methylphenidate on Recovery of Cognitive Function Following Experimental Traumatic Brain Injury In Rats

  2006cites this paper
• Phénotype nicotinique des souris dépourvues du transporteur de la dopamine ou de la protéine STOP : modèles d'étude de symptômes psychiatriques

  2006cites this paper
• Nicotinic receptors and cognition in Parkinson’s Disease: the importance of neuronal synchrony

  2004cites this paper
• ESR study on scavenging effect of nicotine on free radicals

  2003cites this paper
• Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope

  2003cites this paper
• Hippocampal structure and the action of cholinomimetic drugs

  2002cites this paper
• Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?

  2002cites this paper
• Histochemical study of acute and chronic intraperitoneal nicotine effects on several glycolytic and Krebs cycle dehydrogenase activities in the frontoparietal cortex and subcortical nuclei of the rat brain

  2001cites this paper
• Cognitive effects of nicotine.

  2001influential citation
• Mechanisms of ß-Amyloid Neurotoxicity: Perspectives of Pharmacotherapy

  2000cites this paper
• Nicotine improves Morris water task performance in rats given medial frontal cortex lesions.

  2000cites this paper
• Guidelines for the Appropriate Use of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease

  1999cites this paper